⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 4, 2024Open Access

Figure S9 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer

Hirofumi Mikami Shu Feng Yutaka Matsuda Shinya Ishii Sotaro Naoi Yumiko Azuma Hiroaki Nagano Kentaro Asanuma Yoko Kayukawa Toshiaki Tsunenari Shogo Kamikawaji Ryutaro Iwabuchi Junko Shinozuka Masaki Yamazaki Haruka Kuroi Samantha Shu Wen Ho Siok Wan Gan Priyanka Chichili Chai Ling Pang Chiew Ying Yeo Shun Shimizu Naoka Hironiwa Yasuko Kinoshita Yuichiro Shimizu Akihisa Sakamoto Masaru Muraoka Noriyuki Takahashi Tatsuya Kawa Hirotake Shiraiwa Futa Mimoto Kenji Kashima Mika Kamata‐Sakurai Shumpei Ishikawa Hiroyuki Aburatani Takehisa Kitazawa Tomoyuki Igawa

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Supplementary Figure S9. The use of dexamethasone and tocilizumab does not limit the antitumor efficacy of DLL3 trispecific.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mikami et al. (2024) studied this question.

synapsesocial.com/papers/68e664bab6db6435875f152b https://doi.org/10.1158/2326-6066.25964655.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S8 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer2024
2Figure S4 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer2024
3Figure S6 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer2024
4Figure S5 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer2024
5Figure S3 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer2024
6Figure S7 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer2024
7Figure S1 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer2024
8Figure S2 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer2024